JP2011509676A - ヒトＴｈ１７細胞の選択的分化、同定および調節 - Google Patents

ヒトＴｈ１７細胞の選択的分化、同定および調節 Download PDF

Info

Publication number
JP2011509676A
JP2011509676A JP2010543306A JP2010543306A JP2011509676A JP 2011509676 A JP2011509676 A JP 2011509676A JP 2010543306 A JP2010543306 A JP 2010543306A JP 2010543306 A JP2010543306 A JP 2010543306A JP 2011509676 A JP2011509676 A JP 2011509676A
Authority
JP
Japan
Prior art keywords
cells
cell
tgf
podoplanin
blt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010543306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509676A5 (enExample
Inventor
ビジェイ ケー． クヘロー，
デイビッド イー． アンダーソン，
エステル ベッテリー，
デイビッド ハフラー，
モハメド オウッカ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of JP2011509676A publication Critical patent/JP2011509676A/ja
Publication of JP2011509676A5 publication Critical patent/JP2011509676A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
JP2010543306A 2008-01-18 2009-01-21 ヒトＴｈ１７細胞の選択的分化、同定および調節 Pending JP2011509676A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US654108P 2008-01-18 2008-01-18
US3182408P 2008-02-27 2008-02-27
PCT/US2009/031477 WO2009092087A2 (en) 2008-01-18 2009-01-21 Selective differentiation, identification, and modulation of human th17 cells

Publications (2)

Publication Number Publication Date
JP2011509676A true JP2011509676A (ja) 2011-03-31
JP2011509676A5 JP2011509676A5 (enExample) 2013-02-28

Family

ID=40885916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543306A Pending JP2011509676A (ja) 2008-01-18 2009-01-21 ヒトＴｈ１７細胞の選択的分化、同定および調節

Country Status (4)

Country Link
US (1) US20110245107A1 (enExample)
EP (1) EP2238241B1 (enExample)
JP (1) JP2011509676A (enExample)
WO (1) WO2009092087A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019112446A (ja) * 2013-07-23 2019-07-11 バイオコン・リミテッド Ｃｄ６結合パートナーの使用およびそれに基づく方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (en) 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8784898B2 (en) * 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
WO2008115290A2 (en) 2006-10-25 2008-09-25 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US20100310609A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US20100004189A1 (en) * 2007-10-25 2010-01-07 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100008997A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US9523090B2 (en) * 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100303871A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2285347A4 (en) 2008-05-01 2011-09-21 Revalesio Corp COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM
US20100098687A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
EP2460880B1 (en) * 2009-07-29 2014-11-19 Sysmex Corporation Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells
EP2459184A1 (en) * 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
JP5481677B2 (ja) * 2009-12-10 2014-04-23 シャープ株式会社 生体内に蓄積した粒子の分析方法
NZ604063A (en) 2010-05-07 2015-01-30 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
EP2578232A4 (en) * 2010-06-02 2013-11-20 Dainippon Sumitomo Pharma Co TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES
FR2960882B1 (fr) * 2010-06-04 2012-11-16 Hospices Civils Lyon Co-culture de cellules mononucleees et de cellules mesenchymateuses pour l'obtention de cellules productrices d'il-17
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
EP2696849A4 (en) * 2011-04-13 2014-10-29 Revalesio Corp COMPOSITIONS AND METHODS FOR INHIBITING AND / OR MODULATING EFFECTOR CELLS IN INFLAMMABLE NEURODEGENERATIVE ILLNESSES
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2014134351A2 (en) 2013-02-27 2014-09-04 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
WO2020102623A1 (en) * 2018-11-15 2020-05-22 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
US12630603B2 (en) 2020-02-20 2026-05-19 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
WO2022040504A2 (en) * 2020-08-21 2022-02-24 Georgetown University Stem cell-like memory t cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149814A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP2130919A1 (en) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US7622443B2 (en) * 2002-04-26 2009-11-24 California Institute Of Technology Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
ES2389258T3 (es) 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
EP1771204A4 (en) * 2004-07-01 2008-08-13 Univ New York COMPOSITIONS AND METHOD FOR MODULATING ROR-GAMMA-T
WO2008100328A2 (en) * 2006-07-13 2008-08-21 Burnham Institute For Medical Research METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
US8288357B2 (en) * 2007-03-23 2012-10-16 Korea University Research & Business Foundation Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers
US20110136113A1 (en) * 2008-08-27 2011-06-09 Sysmex Corporation Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helper t cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149814A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
JPN6013038627; ＩＶＡＮＯＶ，Ｉ．Ｉ．　ｅｔ　ａｌ．: 'Ｔｒａｎｓｃｒｉｐｔｉｏｎａｌ　ｒｅｇｕｌａｔｉｏｎ　ｏｆ　Ｔｈ１７　ｃｅｌｌ　ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ．' Ｓｅｍｉｎ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１９，　Ｎｏ．６, 200712, ｐｐ．４０９-１７ *
JPN6013038627; Ｓｅｍｉｎａｒｓ　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１９，, 2007, ｐ．４０９-４１７ *
JPN6013038628; Ｎａｔｕｒｅ Ｖｏｌ．４４８, 2007, ｐ．４８０-４８３ *
JPN6013038628; ＮＵＲＩＥＶＡ，Ｒ．　ｅｔ　ａｌ．: 'Ｅｓｓｅｎｔｉａｌ　ａｕｔｏｃｒｉｎｅ　ｒｅｇｕｌａｔｉｏｎ　ｂｙ　ＩＬ-２１　ｉｎ　ｔｈｅ　ｇｅｎｅｒａｔｉｏｎ　ｏｆ　ｉｎｆｌａｍｍａｔｏｒｙ　Ｔ　ｃｅｌｌｓ．' Ｎａｔｕｒｅ Ｖｏｌ．４４８，　Ｎｏ．７１５２, 20070726, ｐｐ．４８０-３ *
JPN6013038629; Ｐａｎｃｒｅａｓ Ｖｏｌ．３１，　Ｎｏ．２, 2005, ｐ．１４８-１５５ *
JPN6013038629; ＱＵ，Ｐ．　ｅｔ　ａｌ．: 'Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ＣＣＬ２１　ａｎｄ　５'-Ｎａｓｅ　ｏｎ　ｐａｎｃｒｅａｔｉｃ　ｌｙｍｐｈａｔｉｃｓ　ｉｎ　ｎｏｎｏｂｅｓｅ　ｄｉａｂｅｔｉｃ　ｍｉｃｅ．' Ｐａｎｃｒｅａｓ Ｖｏｌ．３１，　Ｎｏ．２, 200508, ｐｐ．１４８-５５ *
JPN6013038630; ＩＶＯＳ Ｖｏｌ．４７，　Ｎｏ．４, 2006, ｐ．１５４３-１５４９ *
JPN6013038630; ＬＩＡＯ，Ｔ．　ｅｔ　ａｌ．: 'Ｂｌｏｃｋａｄｅ　ｏｆ　ｔｈｅ　ｉｎｔｅｒａｃｔｉｏｎ　ｏｆ　ｌｅｕｋｏｔｒｉｅｎｅ　ｂ４　ｗｉｔｈ　ｉｔｓ　ｒｅｃｅｐｔｏｒ　ｐｒｅｖｅｎｔｓ　ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ａｕｔｏｉｍｍｕｎｅ　ｕ' Ｉｎｖｅｓｔ．　Ｏｐｈｔｈａｌｍｏｌ．　Ｖｉｓ．　Ｓｃｉ． Ｖｏｌ．４７，　Ｎｏ．４, 200604, ｐｐ．１５４３-９ *
JPN6014022971; ＷＩＬＳＯＮ，Ｎ．Ｊ．　ｅｔ　ａｌ．: 'Ｄｅｖｅｌｏｐｍｅｎｔ，　ｃｙｔｏｋｉｎｅ　ｐｒｏｆｉｌｅ　ａｎｄ　ｆｕｎｃｔｉｏｎ　ｏｆ　ｈｕｍａｎ　ｉｎｔｅｒｌｅｕｋｉｎ　１７-ｐｒｏｄｕｃｉｎｇ　ｈｅｌｐｅｒ　Ｔ　ｃｅｌｌｓ．' Ｎａｔ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．８，　Ｎｏ．９, 200709, ｐｐ．９５０-７ *
JPN6014022972; ＹＡＮＧ，Ｌ．　ｅｔ　ａｌ．: 'ＩＬ-２１　ａｎｄ　ＴＧＦ-ｂｅｔａ　ａｒｅ　ｒｅｑｕｉｒｅｄ　ｆｏｒ　ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ　ｏｆ　ｈｕｍａｎ　Ｔ（Ｈ）１７　ｃｅｌｌｓ．' Ｎａｔｕｒｅ Ｖｏｌ．４５４，　Ｎｏ．７２０２, 20080717, ｐｐ．３５０-２ *
JPN6014022975; ＭＩＹＡＭＯＴＯ，Ｙ．　ｅｔ　ａｌ．: 'Ｐｏｄｏｐｌａｎｉｎ　ｉｓ　ａｎ　ｉｎｆｌａｍｍａｔｏｒｙ　ｐｒｏｔｅｉｎ　ｕｐｒｅｇｕｌａｔｅｄ　ｉｎ　Ｔｈ１７　ｃｅｌｌｓ　ｉｎ　ＳＫＧ　ａｒｔｈｒｉｔｉｃ　ｊｏｉｎｔｓ．' Ｍｏｌ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．５４，　Ｎｏ．２, 201306, ｐｐ．１９９-２０７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019112446A (ja) * 2013-07-23 2019-07-11 バイオコン・リミテッド Ｃｄ６結合パートナーの使用およびそれに基づく方法

Also Published As

Publication number Publication date
WO2009092087A3 (en) 2009-10-15
US20110245107A1 (en) 2011-10-06
EP2238241A4 (en) 2011-08-10
EP2238241B1 (en) 2013-09-11
WO2009092087A2 (en) 2009-07-23
EP2238241A2 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
EP2238241B1 (en) Selective differentiation, identification, and modulation of human th17 cells
JP7067804B2 (ja) がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
US20120213768A1 (en) Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
US20220152176A1 (en) Cancer biomarkers for durable clinical benefit
US20120288499A1 (en) Methods for diagnosis and treatment of cutaneous t cell lymphomas
JP2018506528A (ja) Ｉｂｄにおける治療標的及びバイオマーカー
CN116997663A (zh) 类风湿性关节炎发作的标志物和细胞前因
JP2006512396A (ja) 免疫寛容を誘導および維持する方法
CN107076757A (zh) 基于RGMa片段的诊断测定
US20170003277A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
JP2010004750A (ja) 自己免疫疾患による組織傷害の発症または発症可能性の診断方法、およびその利用
US20240019437A1 (en) Methods for the diagnosis and the treatment of graft-versus-host disease
KR20210004888A (ko) T 세포의 세포 표면 항원 및 이의 다양한 용도
US9732320B2 (en) Selective differentiation, identification, and modulation of human TH17 cells
US20130189282A1 (en) Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin
Natalucci Synovial macrophages in patients with reumatoid arthritis: predictors of response and their modifications to treatment
WO2026080385A1 (en) Bacterial proteins that confer risk of rheumatoid arthritis and related materials and methods
US20150362508A1 (en) Effector t cell rsistance
Rowe Investigation of Conventional T cells from spinal enthesis tissue including pharmacological antagonism
Valma Antigen Specific CD4+ T cells and their role in viral infection and autoimmune disease
Duizendstra Rejection and Tolerance after Liver Transplantation
US20140235543A1 (en) Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors
Ridgley Cytokine mediated CD4+ T-cell dysregulation in early rheumatoid arthritis
Smith The Role of CXCL10 in the Pathogenesis of Rheumatoid Arthritis Joint Damage
WO2008100217A1 (en) Polymorphisms in genes of the cryopyrin inflammasome and their uses in the treatment of inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141120